RU2004126238A - Fab-фрагменты моноклонального антитела человека, направленные против гликопротеина e2 hcv и обладающие нейтрализующей активностью in vitro - Google Patents
Fab-фрагменты моноклонального антитела человека, направленные против гликопротеина e2 hcv и обладающие нейтрализующей активностью in vitro Download PDFInfo
- Publication number
- RU2004126238A RU2004126238A RU2004126238/13A RU2004126238A RU2004126238A RU 2004126238 A RU2004126238 A RU 2004126238A RU 2004126238/13 A RU2004126238/13 A RU 2004126238/13A RU 2004126238 A RU2004126238 A RU 2004126238A RU 2004126238 A RU2004126238 A RU 2004126238A
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- antibodies
- heavy chain
- light chain
- hcv virus
- Prior art date
Links
- 230000003472 neutralizing effect Effects 0.000 title claims abstract 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 title claims 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 title claims 2
- 102000003886 Glycoproteins Human genes 0.000 title abstract 2
- 108090000288 Glycoproteins Proteins 0.000 title abstract 2
- 238000000338 in vitro Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract 5
- 238000002560 therapeutic procedure Methods 0.000 claims abstract 3
- 239000012634 fragment Substances 0.000 claims abstract 2
- 238000001727 in vivo Methods 0.000 claims abstract 2
- 239000002674 ointment Substances 0.000 claims abstract 2
- 230000000699 topical effect Effects 0.000 claims abstract 2
- 229960005486 vaccine Drugs 0.000 claims abstract 2
- 241000700605 Viruses Species 0.000 claims 4
- 101710125507 Integrase/recombinase Proteins 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 239000013060 biological fluid Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 238000003259 recombinant expression Methods 0.000 claims 1
- 239000006216 vaginal suppository Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
- C07K16/109—Hepatitis C virus; Hepatitis G virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Claims (11)
1. Человеческое антитело или его функциональные фрагменты против белка Е2 вируса HCV, отличающееся тем, что оно обладает нейтрализующей активностью in vivo.
2. Антитело по п. 1, являющееся антителом е137, отличающееся тем, что оно имеет следующие последовательности вариабельных частей тяжелой цепи и легкой цепи:
тяжелая цепь е137 (НС)
легкая цепь е137 (LC)
3. Антитело по п. 1, являющееся антителом е301, отличающееся тем, что оно имеет следующие последовательности вариабельных частей тяжелой цепи и легкой цепи:
тяжелая цепь е301 (НС)
легкая цепь е301 (LC)
4. Композиция для терапии против вируса HCV, содержащая терапевтически эффективное количество по крайней мере одного из антител согласно предшествующим пунктам.
5. Композиция по п. 4 для местного применения в виде геля, крема, мази и вагинальных свечей.
6. Применение антитела по пп. 1-3 для создания вакцин против вируса HCV.
7. Нуклеиновая кислота, кодирующая антитело по одному из пп. 1-3.
8. Рекомбинантный экспрессирующий вектор, содержащий нуклеиновую кислоту по п. 7, способный эффективно экспрессировать антитело по пп. 1-3 в прокариотических и эукариотических клетках.
9. Рекомбинантный вектор по п. 8, дополнительно содержащий нуклеотидную последовательность, кодирующую сигнальный пептид, по существу, граничащий с последовательностью, кодирующей антитело по пп. 1-3, способный экспортировать данное антитело из клеточного окружения.
10. Применение рекомбинантного вектора по п. 9 в генной терапии.
11. Способ определения присутствия антител, направленных против различных эпитопов белка Е2 вируса HCV, в биологической жидкости, включающий в себя стадии
а) определения присутствия антител в указанной жидкости, способных ингибировать связывание специфических человеческих Fab-фрагментов, направленных против различных эпитопов белка Е2;
b) установления корреляции между присутствием таким образом титрованных антител и клиническими характеристиками больного, такими как прогноз, отвечаемость на терапию, инфективность.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITRM2002A000049 | 2002-01-30 | ||
| IT2002RM000049A ITRM20020049A1 (it) | 2002-01-30 | 2002-01-30 | Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2004126238A true RU2004126238A (ru) | 2005-04-20 |
Family
ID=11456013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004126238/13A RU2004126238A (ru) | 2002-01-30 | 2003-01-29 | Fab-фрагменты моноклонального антитела человека, направленные против гликопротеина e2 hcv и обладающие нейтрализующей активностью in vitro |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20050084845A1 (ru) |
| EP (1) | EP1476468B9 (ru) |
| JP (1) | JP4287280B2 (ru) |
| KR (1) | KR101002791B1 (ru) |
| CN (1) | CN1856508A (ru) |
| AT (1) | ATE407147T1 (ru) |
| AU (1) | AU2003208000B2 (ru) |
| CA (1) | CA2474801C (ru) |
| DE (1) | DE60323333D1 (ru) |
| DK (1) | DK1476468T3 (ru) |
| EA (1) | EA009861B1 (ru) |
| ES (1) | ES2314179T3 (ru) |
| IT (1) | ITRM20020049A1 (ru) |
| NZ (1) | NZ534922A (ru) |
| RU (1) | RU2004126238A (ru) |
| WO (1) | WO2003064473A2 (ru) |
| ZA (1) | ZA200406187B (ru) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7611709B2 (en) * | 2004-05-10 | 2009-11-03 | Boehringer Ingelheim Pharma Gmbh And Co. Kg | 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives |
| US7723306B2 (en) | 2004-05-10 | 2010-05-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation |
| US7727962B2 (en) | 2004-05-10 | 2010-06-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Powder comprising new compositions of oligosaccharides and methods for their preparation |
| ITTO20070066A1 (it) | 2007-01-30 | 2008-07-31 | Pomona Biotechnologies Llc | Anticorpi monoclonali anti-idiotipo mimotopi dell'antigene gp 120 di hiv |
| WO2008107187A1 (en) * | 2007-03-06 | 2008-09-12 | Ribovax Biotechnologies S.A. | Antibodies specific for rubella virus |
| EP2177535A4 (en) | 2007-07-25 | 2010-08-25 | Jp Nat Inst Infectious Disease | ANTIBODIES HAVING INHIBITORY ACTIVITY ON HEPATITIS C VIRUS INFECTION (HCV) AND USE THEREOF |
| WO2009081285A2 (en) * | 2007-12-17 | 2009-07-02 | Medical Research Council Technology | Hepatitis c virus antibodies |
| ITTO20080204A1 (it) | 2008-03-17 | 2009-09-18 | Pomona Biotechnologies Llc | Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a |
| ITTO20080398A1 (it) | 2008-05-27 | 2009-11-28 | Pomona Biotechnologies Llc | Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1 |
| WO2010035292A1 (en) * | 2008-09-24 | 2010-04-01 | Natimab Therapeutics S.R.L. | The use of a human monoclonal anti-hcv antibody as a medicament for the therapeutic treatment and prevention of hcv infections |
| US20100104555A1 (en) * | 2008-10-24 | 2010-04-29 | The Scripps Research Institute | HCV neutralizing epitopes |
| ITTO20080964A1 (it) * | 2008-12-22 | 2010-06-23 | Natimab Therapeutics S R L | Anticorpo monoclonale anti-hcv come medicamento per il trattamento terapeutico e la prevenzione di infezioni da hcv |
| IT1395961B1 (it) | 2009-06-01 | 2012-11-02 | Pomona Biotechnologies Llc | Anticorpi monoclonali come medicamento per il trattamento terapeutico e/o profilattico delle infezioni da virus influenzale a (h1n1) di origine suina (s-oiv) |
| JP5756757B2 (ja) | 2009-10-30 | 2015-07-29 | 東レ株式会社 | Ｃ型肝炎ウイルス（ｈｃｖ）に対して感染阻害活性を有する抗体及びその用途 |
| AU2011223906B2 (en) | 2010-03-01 | 2015-06-25 | Vincent Agnello | Prognostic marker for cryoglobulinemic vasculitis and B cell malignancies in HCV infected patients |
| CN104119436B (zh) * | 2013-04-27 | 2016-12-28 | 中国科学院上海生命科学研究院 | 抗丙型肝炎病毒的中和性全人单克隆抗体 |
| GB201415714D0 (en) * | 2014-09-05 | 2014-10-22 | Medical Res Council | Antibodies and antigen binding fragments thereof |
| CN105254756B (zh) * | 2015-11-27 | 2018-09-07 | 武汉大学 | 一种针对丙型肝炎病毒包膜蛋白e2的单克隆抗体及应用 |
| KR20180001380U (ko) | 2016-10-31 | 2018-05-10 | 대우조선해양 주식회사 | 해양구조물의 발로 작동시키는 캡스탄 |
| CN118459598A (zh) | 2019-12-27 | 2024-08-09 | 凯奥目生物科学株式会社 | 抗cdcp1抗体 |
| WO2022049867A1 (ja) | 2020-09-02 | 2022-03-10 | 国立大学法人東京大学 | がん免疫微小環境の調節物質およびそれによる予防・診断・治療的利用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000005266A1 (en) * | 1998-07-21 | 2000-02-03 | Connex Gesellschaft Zur Optimierung Von Forschung Und Entwicklung Mbh | Anti hepatitis c virus antibody and uses thereof |
| US7091324B2 (en) * | 1998-11-05 | 2006-08-15 | Board Of Trustees Of Leland Stanford Junior University | Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes |
| WO2002005560A2 (en) | 2000-07-12 | 2002-01-17 | General Instrument Corporation | Method and apparatus for downloading objects via an inband channel with minimal subscriber impact |
| EP1355947A2 (en) * | 2000-12-01 | 2003-10-29 | The Government of the United States of America, as Represented by the Secretary, Department of Health and Human Services | Monoclonal antibodies specific for the e2 glycoprotein of hepatitis c virus and their use in the diagnosis, treatment, and prevention of hepatitis c |
-
2002
- 2002-01-30 IT IT2002RM000049A patent/ITRM20020049A1/it unknown
-
2003
- 2003-01-29 EA EA200401081A patent/EA009861B1/ru not_active IP Right Cessation
- 2003-01-29 CN CNA038030926A patent/CN1856508A/zh active Pending
- 2003-01-29 DK DK03705004T patent/DK1476468T3/da active
- 2003-01-29 US US10/502,307 patent/US20050084845A1/en not_active Abandoned
- 2003-01-29 AT AT03705004T patent/ATE407147T1/de not_active IP Right Cessation
- 2003-01-29 KR KR1020047011208A patent/KR101002791B1/ko active IP Right Grant
- 2003-01-29 DE DE60323333T patent/DE60323333D1/de not_active Expired - Lifetime
- 2003-01-29 NZ NZ534922A patent/NZ534922A/en not_active IP Right Cessation
- 2003-01-29 CA CA2474801A patent/CA2474801C/en not_active Expired - Lifetime
- 2003-01-29 ES ES03705004T patent/ES2314179T3/es not_active Expired - Lifetime
- 2003-01-29 JP JP2003564093A patent/JP4287280B2/ja not_active Expired - Fee Related
- 2003-01-29 EP EP03705004A patent/EP1476468B9/en not_active Expired - Lifetime
- 2003-01-29 WO PCT/IT2003/000032 patent/WO2003064473A2/en active IP Right Grant
- 2003-01-29 RU RU2004126238/13A patent/RU2004126238A/ru not_active Application Discontinuation
- 2003-01-29 AU AU2003208000A patent/AU2003208000B2/en not_active Ceased
-
2004
- 2004-08-03 ZA ZA200406187A patent/ZA200406187B/en unknown
-
2008
- 2008-05-28 US US12/128,344 patent/US7727529B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ATE407147T1 (de) | 2008-09-15 |
| ZA200406187B (en) | 2006-06-28 |
| AU2003208000B2 (en) | 2010-05-20 |
| CN1856508A (zh) | 2006-11-01 |
| WO2003064473A3 (en) | 2003-12-24 |
| EA200401081A1 (ru) | 2005-10-27 |
| WO2003064473A2 (en) | 2003-08-07 |
| DK1476468T3 (da) | 2009-01-19 |
| ITRM20020049A0 (it) | 2002-01-30 |
| EA009861B1 (ru) | 2008-04-28 |
| KR20040077745A (ko) | 2004-09-06 |
| CA2474801C (en) | 2012-03-20 |
| EP1476468B1 (en) | 2008-09-03 |
| NZ534922A (en) | 2008-07-31 |
| EP1476468A2 (en) | 2004-11-17 |
| EP1476468B9 (en) | 2009-04-08 |
| CA2474801A1 (en) | 2003-08-07 |
| ES2314179T3 (es) | 2009-03-16 |
| US7727529B2 (en) | 2010-06-01 |
| US20080241162A1 (en) | 2008-10-02 |
| JP4287280B2 (ja) | 2009-07-01 |
| US20050084845A1 (en) | 2005-04-21 |
| KR101002791B1 (ko) | 2010-12-21 |
| DE60323333D1 (de) | 2008-10-16 |
| ITRM20020049A1 (it) | 2003-07-30 |
| JP2005531286A (ja) | 2005-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2004126238A (ru) | Fab-фрагменты моноклонального антитела человека, направленные против гликопротеина e2 hcv и обладающие нейтрализующей активностью in vitro | |
| JP4294596B2 (ja) | 糸球体腎炎および他の炎症性疾患の治療のための組成物および方法 | |
| RU2207878C2 (ru) | "очеловеченные" антитела против gp39 человека, композиции, содержащие эти антитела, и их терапевтическое использование | |
| NZ513498A (en) | Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases | |
| JP2005531286A5 (ru) | ||
| ES2394018T3 (es) | Procedimientos para el diagnóstico y el tratamiento de cánceres derivados de células epiteliales | |
| JP2005503789A5 (ru) | ||
| EA200970477A1 (ru) | Человеческие моноклональные антитела к btla и способы применения | |
| HUP0400284A2 (hu) | Rekombináns, tumorspecifikus ellenanyag és alkalmazása | |
| AR072039A1 (es) | Anticuerpos contra el virus de la hepatitis c | |
| Karniychuk et al. | Porcine reproductive and respiratory syndrome virus infection is associated with an increased number of Sn-positive and CD8-positive cells in the maternal–fetal interface | |
| AU2003208000A1 (en) | Human monoclonal antibody fab fragments directed against HCV E2 glycoprotein and endowed with in vitro neutralizing activity | |
| JP2016538297A5 (ru) | ||
| DE69029808D1 (de) | Monoklonale antikörper | |
| WO1999005175A3 (en) | Diagnosis and treatment of diseases using anti-anti-t-cell receptor vbeta anti-bodies or peptides which are recognized by said antibodies, and endocrine secretion regulatory protein i (esrp1) | |
| DK1417222T3 (da) | Isolerede polypeptider baseret på den neutraliserende epitop af p17-proteinet fra HIV egnet til vacciner samt neutraliserende anti-p17-antistoffer, der specifikt genkender nævnte neutraliserende epitop | |
| WO2005105993A1 (ja) | Ｈｌａ結合性ペプチド、その前駆体、それをコードするｄｎａ断片および組み換えベクター | |
| US20240002479A1 (en) | Single-chain antibody against flavivirus ns1 protein | |
| KR930703444A (ko) | 어류 황체화 호르몬-방출 호르몬 동족체 | |
| Gornowicz-Porowska et al. | Clinical immunology Cutaneous expressions of interleukin-6 and neutrophil elastase as well as levels of serum IgA antibodies to gliadin nonapeptides, tissue transglutaminase and epidermal transglutaminase: implications for both autoimmunity and autoinflammation involvement in dermatitis herpetiformis | |
| Savoysky et al. | Efficient purification of a full length and biochemically active p110Rb, the retinoblastoma gene product | |
| Park et al. | Effect of a monoclonal antibody against human relaxin-2 on cancer cell growth inhibition | |
| Amin et al. | Osteopontin: An innate inhibitor of inflammation activating via alphaVbeta3 integrin in human osteoarthritis | |
| US20190317094A1 (en) | Zika Virus Assay Systems | |
| WO2004011496A3 (en) | Novel t-cell proteins, peptides and antibodies derived therefrom and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20060310 |